These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30778915)

  • 21. Veterinary pharmacovigilance. Part 2. Veterinary pharmacovigilance in practice -- the operation of a spontaneous reporting scheme in a European Union country -- the UK, and schemes in other countries.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):149-70. PubMed ID: 15842305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thirteen years of medication alerts issued by the Brazilian Health Regulatory Agency (ANVISA): What is the profile?
    Ferreira VC; Ferreira GC; Baldoni AO
    J Eval Clin Pract; 2020 Jun; 26(3):957-961. PubMed ID: 31290584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].
    Xie YM; Tian F
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2963-8. PubMed ID: 24471312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacovigilance risk mitigation plans: action in public health to promote the safe use of medication.
    Botelho SF; Reis AM
    Cien Saude Colet; 2015 Dec; 20(12):3897-905. PubMed ID: 26691813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Governance and pharmacovigilance in Brazil: a scoping review.
    Moscou K; Kohler JC; MaGahan A
    J Pharm Policy Pract; 2016; 9():3. PubMed ID: 26862438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance activities in ASEAN countries.
    Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strengths and Weaknesses of the Pharmacovigilance Systems in Three Arab Countries: A Mixed-Methods Study Using the WHO Pharmacovigilance Indicators.
    Garashi H; Steinke D; Schafheutle E
    Int J Environ Res Public Health; 2022 Feb; 19(5):. PubMed ID: 35270208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacovigilance in Italy: An overview.
    Mazzitello C; Esposito S; De Francesco AE; Capuano A; Russo E; De Sarro G
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S20-8. PubMed ID: 24347976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the Current State of Pharmacovigilance System in Pakistan Using Indicator-Based Assessment Tool.
    Khan MAA; Hamid S; Ur-Rehman T; Babar ZU
    Front Pharmacol; 2021; 12():789103. PubMed ID: 35095498
    [No Abstract]   [Full Text] [Related]  

  • 36. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of pharmacovigilance regulatory structures, processes, and outcomes in the Asia-Pacific region: Survey results from 15 countries.
    Shin JY; Shin E; Jeong HE; Kim JH; Lee EK
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):362-369. PubMed ID: 30648304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance?
    Bagheri H; Lacroix I; Guitton E; Damase-Michel C; Montastruc JL
    Therapie; 2016 Apr; 71(2):235-9. PubMed ID: 27080844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements.
    Maigetter K; Pollock AM; Kadam A; Ward K; Weiss MG
    Int J Health Policy Manag; 2015 Mar; 4(5):295-305. PubMed ID: 25905480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of the knowledge and perceptions of pharmacy students on pharmacovigilance activities in Nigeria.
    Osemene KP; Afolabi MO
    BMC Res Notes; 2017 Jul; 10(1):273. PubMed ID: 28697738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.